Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - NetLoans - NetMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Cash & Equivalents (2017 - 2025)

Creative Medical Technology Holdings has reported Cash & Equivalents over the past 16 years, most recently at $7.2 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 21.34% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 21.34% year-over-year, with the annual reading at $7.2 million for FY2025, 21.34% up from the prior year.
  • Cash & Equivalents was $7.2 million for Q4 2025 at Creative Medical Technology Holdings, up from $5.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $22.9 million in Q2 2022 and troughed at $158588.0 in Q2 2021.
  • The 5-year median for Cash & Equivalents is $6.9 million (2025), against an average of $7.4 million.
  • Biggest five-year swings in Cash & Equivalents: soared 14317.02% in 2022 and later tumbled 82.55% in 2023.
  • Tracing CELZ's Cash & Equivalents over 5 years: stood at $10.7 million in 2021, then dropped by 22.41% to $8.3 million in 2022, then tumbled by 58.33% to $3.5 million in 2023, then surged by 71.35% to $5.9 million in 2024, then rose by 21.34% to $7.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $7.2 million, $5.4 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.